AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8973677 — intervention group
Group type: EXPERIMENTAL
Intervention: RigiScan portable home monitor
Number of subjects: 10
Study 8973677 — intervention group
Group type: EXPERIMENTAL
Intervention: RigiScan Plus quantitative program
Number of subjects: 10
Study 8973677 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical estimate of penetrable rigidity
Number of subjects: 10
Study 1458665 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% amorolfine nail lacquer, once-weekly
Number of subjects: 0
Study 1458665 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% amorolfine nail lacquer, twice-weekly
Number of subjects: 0
Study 3974889 — intervention group
Group type: EXPERIMENTAL
Intervention: True plasmapheresis (PP)
Number of subjects: 54
Study 3974889 — intervention group
Group type: COMPARATOR
Intervention: Sham plasmapheresis (sham PP)
Number of subjects: 54
Study 29565472 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel device (LINGUAL RING Ri.P.A.Ra) applied for a maximum of three months
Number of subjects: 80
Study 29565472 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no treatment
Number of subjects: 80
Study 27116921 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 12
Study 27116921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 25566783 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive primary care approach with in-home assessment and interdisciplinary care
Number of subjects: 346
Study 25566783 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 346
Study 25566783 — intervention group
Group type: EXPERIMENTAL
Intervention: Proactive primary care approach
Number of subjects: 346
Study 23419356 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided suprascapular nerve block (UG SNB)
Number of subjects: 52
Study 23419356 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiology-guided suprascapular nerve block (EG SNB)
Number of subjects: 52
Study 23419356 — intervention group
Group type: COMPARATOR
Intervention: Blind suprascapular nerve block (control group)
Number of subjects: 52
Study 20130492 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy (HT)
Number of subjects: 493
Study 20130492 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs)
Number of subjects: 493
Study 20130492 — intervention group
Group type: EXPERIMENTAL
Intervention: No breast-feeding
Number of subjects: 493
Study 20130492 — intervention group
Group type: EXPERIMENTAL
Intervention: Common exposure to both OCs and HT
Number of subjects: 493
Study 20130492 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression model
Number of subjects: 493
Study 20130492 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve of the logistic function
Number of subjects: 493
Study 19512937 — intervention group
Group type: EXPERIMENTAL
Intervention: efavirenz (EFV) + zidovudine/lamivudine
Number of subjects: 106
Study 19512937 — intervention group
Group type: COMPARATOR
Intervention: lopinavir/ritonavir (LPV/r) + zidovudine/lamivudine
Number of subjects: 106
Study 15681688 — intervention group
Group type: EXPERIMENTAL
Intervention: iohexol
Number of subjects: 47
Study 15681688 — intervention group
Group type: COMPARATOR
Intervention: iodixanol
Number of subjects: 47
Study 12856210 — intervention group
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated; DAA)
Number of subjects: 386
Study 12856210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study 10230741 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid extract of Echinacea purpurea (4 mL twice a day)
Number of subjects: 108
Study 10230741 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4 mL juice twice a day)
Number of subjects: 108
Study 10230741 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid extract of Echinacea purpurea
Number of subjects: 108
Study 10230741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 8906176 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic ischemia with warm blood cardioplegia
Number of subjects: 720
Study 8906176 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer LTOC
Number of subjects: 720
Study 1867225 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine
Number of subjects: 58
Study 1867225 — intervention group
Group type: COMPARATOR
Intervention: Oral sustained-release verapamil (verapamil-SR)
Number of subjects: 58
Study 6344906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cadexomer iodine
Number of subjects: 93
Study 6344906 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment combined with compression bandages
Number of subjects: 93
Study 26398184 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI
Number of subjects: 0
Study 26398184 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 0
Study 27223668 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride (25-50 mg/d)
Number of subjects: 60
Study 27223668 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (10-20 mg/d)
Number of subjects: 60
Study 24126070 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-onset ACS presentation
Number of subjects: 893
Study 24126070 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-onset ACS presentation
Number of subjects: 893
Study 24126070 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate analysis of delay factors
Number of subjects: 893
Study 22816227 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 5 mg once daily
Number of subjects: 171
Study 22816227 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 19925256 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaviscon Double Action Liquid (GDAL)
Number of subjects: 0
Study 19925256 — intervention group
Group type: COMPARATOR
Intervention: Gaviscon Liquid (GL)
Number of subjects: 0
Study 18054420 — intervention group
Group type: EXPERIMENTAL
Intervention: silymarin (0.8 g/day)
Number of subjects: 0
Study 18054420 — intervention group
Group type: EXPERIMENTAL
Intervention: silymarin+yacon (0.8+2.4 g/day)
Number of subjects: 0
Study 18054420 — intervention group
Group type: EXPERIMENTAL
Intervention: silymarin+maca (0.6+0.2 g/day)
Number of subjects: 0
Study 18054420 — intervention group
Group type: EXPERIMENTAL
Intervention: maca (0.6 g/day)
Number of subjects: 0
Study 18054420 — intervention group
Group type: EXPERIMENTAL
Intervention: silymarin+yacon
Number of subjects: 0
Study 18054420 — intervention group
Group type: EXPERIMENTAL
Intervention: maca (high doses)
Number of subjects: 0
Study 16386979 — intervention group
Group type: EXPERIMENTAL
Intervention: PC IOL
Number of subjects: 143
Study 16386979 — intervention group
Group type: EXPERIMENTAL
Intervention: AC IOL
Number of subjects: 143
Study 16386979 — intervention group
Group type: COMPARATOR
Intervention: ICS group
Number of subjects: 143
Study 12755242 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg prostaglandin E2 vaginal tablets
Number of subjects: 241
Study 12755242 — intervention group
Group type: COMPARATOR
Intervention: 3 mg prostaglandin E2 vaginal tablets
Number of subjects: 241
Study 10996361 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with triple vessel disease (TVD)
Number of subjects: 97
Study 10996361 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with normal coronary angiogram (NCA)
Number of subjects: 97
Study 10996361 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CD105 with active TGFbeta1 and (a+l)TGFbeta1
Number of subjects: 97
Study 10996361 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of CD105 with TGFbeta3 and CD105/TGFbeta3 complexes
Number of subjects: 97
Study 9229826 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate aerosol treatment
Number of subjects: 49
Study 9229826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 8317408 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg at bedtime
Number of subjects: 361
Study 8317408 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 361
Study 3315425 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer feedback of weighting
Number of subjects: 0
Study 3315425 — intervention group
Group type: COMPARATOR
Intervention: Outcome feedback alone (Control)
Number of subjects: 0
Study 29133365 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking (at the time of diagnosis)
Number of subjects: 1888
Study 29133365 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked 20 or more years
Number of subjects: 1888
Study 29133365 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoked within 5 years of diagnosis
Number of subjects: 1888
Study 26363332 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 76
Study 26363332 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 76
Study 25346026 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure at specific acupoints (Fengchi (GB20), Baihui (GV20), Shenmen (HT7), Niguan (PC6), Yingtang (EX-HN3))
Number of subjects: 99
Study 25346026 — intervention group
Group type: COMPARATOR
Intervention: Sham-acupressure (pressure on five non-acupoints)
Number of subjects: 99
Study 25346026 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no intervention apart from nursing home care)
Number of subjects: 99
Study 23122405 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg of PPTA
Number of subjects: 31
Study 23122405 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg/kg of PPTA
Number of subjects: 31
Study 23122405 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg of PPTA
Number of subjects: 31
Study 20187249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy approaches to increase levels of endogenous dopamine or enhance the function of levodopa
Number of subjects: 0
Study 20187249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene therapy approaches to normalize basal ganglia circuitry by reducing PD-related overactivity of specific brain structures
Number of subjects: 0
Study 20187249 — intervention group
Group type: EXPERIMENTAL
Intervention: Gene delivery of trophic factors to augment dopaminergic function
Number of subjects: 0
Study 17850566 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuff pressure measurement during insertion of a gastric tube
Number of subjects: 30
Study 17850566 — intervention group
Group type: COMPARATOR
Intervention: Measurement of exhaled CO2 through the gastric tube
Number of subjects: 30
Study 16076684 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-positive subjects
Number of subjects: 912
Study 16076684 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori-negative subjects
Number of subjects: 912
Study 16076684 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA-positive H. pylori-positive subjects
Number of subjects: 912
Study 16076684 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA-positive H. pylori-negative subjects
Number of subjects: 912
Study 16076684 — intervention group
Group type: COMPARATOR
Intervention: PCA-negative H. pylori-negative subjects
Number of subjects: 912
Study 11743305 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrupted current delivery
Number of subjects: 12
Study 11743305 — intervention group
Group type: COMPARATOR
Intervention: Continuous current delivery
Number of subjects: 12
Study 11743305 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods
Number of subjects: 12
Study 19667500 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine XR (37.5 to 225 mg once daily)
Number of subjects: 0
Study 19667500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9457980 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum creatine kinase levels in tubal pregnancies
Number of subjects: 90
Study 9457980 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum creatine kinase levels in normal pregnancies (control group)
Number of subjects: 90
Study 9457980 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum creatine kinase levels in missed abortions
Number of subjects: 90
Study 9457980 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum creatine kinase levels in pelvic inflammatory disease
Number of subjects: 90
Study 9457980 — intervention group
Group type: COMPARATOR
Intervention: Maternal serum creatine kinase levels in acute appendicitis
Number of subjects: 90
Study 1771401 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumajecta and Vasolastine (R & V)
Number of subjects: 34
Study 1771401 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 34
Study 7137200 — intervention group
Group type: EXPERIMENTAL
Intervention: Active alcoholics
Number of subjects: 625
Study 7137200 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholics
Number of subjects: 625
Study 7137200 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients initially classified as alcoholic
Number of subjects: 625
Study 30686103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BP target arm (<130 mm Hg)
Number of subjects: 2454
Study 30686103 — intervention group
Group type: COMPARATOR
Intervention: Higher BP target arm (130 to 149 mm Hg)
Number of subjects: 2454
Study 29254910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention messages delivered via the Tú decides app
Number of subjects: 1310
Study 29254910 — intervention group
Group type: COMPARATOR
Intervention: Control messages about trial participation
Number of subjects: 1310
Study 26881208 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intranasal deslorelin (GnRHa) with concurrent administration of low-dose estradiol (E2) ± testosterone (T) for 6 months
Number of subjects: 0
Study 26881208 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily intranasal deslorelin (GnRHa) with concurrent administration of low-dose estradiol (E2) ± testosterone (T)
Number of subjects: 0
Study 23595613 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebamipide 100 mg three times daily for 4 weeks
Number of subjects: 61
Study 23595613 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 22095057 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School program (BSG, N.=29)
Number of subjects: 50
Study 22095057 — intervention group
Group type: COMPARATOR
Intervention: Medical assistance (CG, N.=21)
Number of subjects: 50
Study 20595542 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating current EMS (2.5 kHz delivered at 75 Hz, 400 micros)
Number of subjects: 12
Study 20595542 — intervention group
Group type: COMPARATOR
Intervention: Pulsed current EMS (75 Hz, 400 micros)
Number of subjects: 12
Study 20595542 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating current EMS
Number of subjects: 12
Study 20595542 — intervention group
Group type: COMPARATOR
Intervention: Pulsed current EMS
Number of subjects: 12
Study 20595542 — intervention group
Group type: EXPERIMENTAL
Intervention: Both EMS conditions
Number of subjects: 12
Study 18047925 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan (8 mg/day)
Number of subjects: 95
Study 18047925 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan (80 mg/day)
Number of subjects: 95
Study 18047925 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (25 mg/day) for 3 months
Number of subjects: 95
Study 18047925 — intervention group
Group type: COMPARATOR
Intervention: Candesartan and Valsartan (both groups)
Number of subjects: 95
Study 15650042 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial counselling intervention (three sessions with a social worker trained in Experiential Psychosocial Therapy: one before, one during, and one after the first IVF cycle)
Number of subjects: 84
Study 15650042 — intervention group
Group type: COMPARATOR
Intervention: Routine-care control group
Number of subjects: 84
Study 12395333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 120 mg/d (TMX120)
Number of subjects: 329
Study 12395333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 60 mg/d (TMX60)
Number of subjects: 329
Study 12395333 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 329
Study 10092165 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxation training (30 minutes, twice a week for 10 weeks)
Number of subjects: 68
Study 10092165 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68
Study 7594701 — intervention group
Group type: EXPERIMENTAL
Intervention: cp-45 vaccine (10^4 or 10^5 TCID50)
Number of subjects: 114
Study 7594701 — intervention group
Group type: EXPERIMENTAL
Intervention: cp-45 vaccine (10^5 TCID50)
Number of subjects: 114
Study 2316411 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led intervention
Number of subjects: 998
Study 2316411 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led intervention with booster sessions
Number of subjects: 998
Study 2316411 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led intervention
Number of subjects: 998
Study 2316411 — intervention group
Group type: EXPERIMENTAL
Intervention: Teacher-led intervention with booster sessions
Number of subjects: 998
Study 2316411 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 998
Study 6576204 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation doses of less than or equal to 18 Gy
Number of subjects: 275
Study 6576204 — intervention group
Group type: COMPARATOR
Intervention: Radiation doses of 24 Gy
Number of subjects: 275
Study 6576204 — intervention group
Group type: COMPARATOR
Intervention: Intensive systemic reinduction therapy
Number of subjects: 275
Study 30859618 — intervention group
Group type: EXPERIMENTAL
Intervention: Monovalent PHF vaccine administered at separate sites
Number of subjects: 91
Study 30859618 — intervention group
Group type: COMPARATOR
Intervention: Multivalent PHF/Rabies vaccine administered at a single site
Number of subjects: 91
Study 28406122 — intervention group
Group type: COMPARATOR
Intervention: Mechanical treatment (Group M)
Number of subjects: 11
Study 28406122 — intervention group
Group type: COMPARATOR
Intervention: Diode laser disinfection (Group L)
Number of subjects: 11
Study 28406122 — intervention group
Group type: COMPARATOR
Intervention: Combination of mechanical treatment and diode laser (Group M + L)
Number of subjects: 11
Study 25641925 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss during neoadjuvant chemotherapy (NCT)
Number of subjects: 66
Study 25641925 — intervention group
Group type: COMPARATOR
Intervention: Weight gain during neoadjuvant chemotherapy (NCT)
Number of subjects: 66
Study 25641925 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (BMI<25 kg/m(2)), overweight (BMI ≥25 and <30 kg/m(2)), and obese (BMI ≥30 kg/m(2)) classifications
Number of subjects: 66
Study 24835038 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced depression treatment for 6 months
Number of subjects: 157
Study 24835038 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 157
Study 22092962 — intervention group
Group type: EXPERIMENTAL
Intervention: Metallic cannula
Number of subjects: 25
Study 22092962 — intervention group
Group type: COMPARATOR
Intervention: Standard needle
Number of subjects: 25
Study 19671312 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐branched renal artery (Group A)
Number of subjects: 298
Study 19671312 — intervention group
Group type: EXPERIMENTAL
Intervention: Double‐branched renal arteries (Group B)
Number of subjects: 298
Study 19671312 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal arteries with 2 or more branches (Group C)
Number of subjects: 298
Study 20077276 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid ingestion
Number of subjects: 9
Study 20077276 — intervention group
Group type: COMPARATOR
Intervention: No fluid ingestion (control)
Number of subjects: 9
Study 15665029 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 65
Study 15665029 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva substitute
Number of subjects: 65
Study 15665029 — intervention group
Group type: COMPARATOR
Intervention: Chewing gum and saliva substitute
Number of subjects: 65
Study 12000201 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 12000201 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 0
Study 12000201 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0
Study 12000201 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide
Number of subjects: 0
Study 12000201 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine
Number of subjects: 0
Study 9721763 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopically assisted vaginal hysterectomy
Number of subjects: 65
Study 9721763 — intervention group
Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 65
Study 7930726 — intervention group
Group type: EXPERIMENTAL
Intervention: Fc gamma RIIa‐R/R131 allotype
Number of subjects: 25
Study 7930726 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutrophils with the Fc gamma RIIa‐R/R131 allotype
Number of subjects: 25
Study 3357182 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention involving a packet of printed material and a 5- to 15-minute review with a physician and educator.
Number of subjects: 0
Study 3357182 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 0
Study 31462178 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based multi-component intervention for secondary prevention of stroke
Number of subjects: 0
Study 31462178 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 30007332 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention based on the Health Belief Model; conducted over two sessions each lasting for 60 min
Number of subjects: 100
Study 30007332 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 100
Study 27788679 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait rehabilitation program using augmented reality (20 sessions of 30 minutes over 4 weeks)
Number of subjects: 70
Study 27788679 — intervention group
Group type: COMPARATOR
Intervention: Standard treadmill training (similar frequency and intensity to the intervention)
Number of subjects: 70